{"gene":"LYAR","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":1993,"finding":"LYAR was identified as a novel nucleolar zinc finger protein containing a zinc finger DNA-binding motif and three nuclear localization signals. Immunolocalization showed predominant nucleolar localization. Overexpression of LYAR in fibroblasts increased tumor formation in nude mice, establishing LYAR as a candidate nucleolar oncoprotein involved in cell growth regulation.","method":"cDNA cloning, immunolocalization, Western blot, retroviral overexpression with in vivo tumor assay","journal":"Genes & Development","confidence":"High","confidence_rationale":"Tier 2 — foundational paper with multiple orthogonal methods (immunolocalization, immunoprecipitation, functional tumor assay), highly cited","pmids":["8491376"],"is_preprint":false},{"year":2014,"finding":"Lyar was found to associate with cytoplasmic ribosomes in rodent testis and cancer cells, specifically with the 60S large ribosomal subunit but not polysomes. Overexpression of Lyar increased translation in vitro, providing the first experimental link between LYAR and translational control.","method":"Proteomic survey, subcellular fractionation, ultracentrifugation, in vitro translation assay","journal":"Molecular and Cellular Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple biochemical methods in a single study but single lab","pmids":["24990247"],"is_preprint":false},{"year":2015,"finding":"LYAR was characterized as a transcription factor that directly binds the LGALS1 (galectin-1) promoter to upregulate galectin-1 expression, thereby promoting migration and invasion of colorectal cancer cells. Ectopic galectin-1 expression partially rescued migration in LYAR knockdown cells.","method":"ChIP assay, gene reporter assay, siRNA knockdown, rescue experiment, migration/invasion assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and reporter assay with rescue experiment, single lab","pmids":["26413750"],"is_preprint":false},{"year":2015,"finding":"Lyar was identified as a ligand for retinal pigment epithelial (RPE) phagocytosis. Cytoplasmic Lyar released from apoptotic cells selectively bound to shed photoreceptor outer segments (POSs) and apoptotic cells but not healthy cells, and POS vesicles engulfed via the Lyar-dependent pathway were targeted to Rab7-positive phagosomes.","method":"Open reading frame phage display, functional cloning, immunohistochemistry, colocalization with phagosome marker Rab7","journal":"Journal of Cellular Biochemistry","confidence":"Medium","confidence_rationale":"Tier 3 — novel ligand identification with functional phagosome colocalization, single lab","pmids":["25735755"],"is_preprint":false},{"year":2017,"finding":"N-Myc was shown to upregulate LYAR gene expression by binding to its promoter. LYAR forms a protein complex with PRMT5. Knockdown of LYAR upregulated oxidative stress genes including CHAC1 (which depletes glutathione), leading to oxidative stress, growth inhibition, and apoptosis in neuroblastoma cells. Co-treatment with N-acetyl-l-cysteine or CHAC1 siRNA rescued LYAR knockdown phenotypes, placing LYAR in a pathway that suppresses oxidative stress downstream of N-Myc.","method":"Promoter ChIP, siRNA knockdown, genome-wide gene expression, co-IP (LYAR-PRMT5 complex), rescue experiments with NAC and CHAC1 siRNA","journal":"Cell Death and Differentiation","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including promoter binding, complex identification, epistasis rescue, single lab but comprehensive","pmids":["28686580"],"is_preprint":false},{"year":2018,"finding":"LYAR selectively recruits BRD2 to chromatin at specific promoters including Nanog. Under differentiation conditions, Lyar-mediated recruitment of Brd2 moderates Nanog downregulation; loss of Lyar leads to impaired Nanog downregulation and defective differentiation. A truncated Lyar lacking the Brd2-interacting domain phenocopied Brd2 depletion, confirming that direct LYAR-BRD2 interaction is required for chromatin recruitment.","method":"ChIP, siRNA knockdown, domain deletion mutagenesis (truncated Lyar), BET inhibitor treatment, differentiation assays","journal":"Journal of Molecular Biology","confidence":"High","confidence_rationale":"Tier 2 — ChIP with domain mutagenesis and functional differentiation readout, multiple orthogonal approaches","pmids":["29505757"],"is_preprint":false},{"year":2018,"finding":"During influenza A virus infection, LYAR expression is increased and LYAR translocates from the nucleolus to the nucleoplasm and cytoplasm. LYAR interacts with viral RNP (vRNP) subunits, enhancing vRNP assembly and thereby facilitating viral RNA synthesis and influenza A virus replication.","method":"Affinity purification–mass spectrometry (AP-MS), co-IP, subcellular fractionation, viral RNA synthesis assays, knockdown","journal":"Journal of Virology","confidence":"High","confidence_rationale":"Tier 2 — AP-MS identification followed by co-IP validation and functional RNA synthesis assay, mechanistically coherent","pmids":["30209172"],"is_preprint":false},{"year":2019,"finding":"LYAR enhances rDNA transcription by binding BRD2 (independent of bromodomain acetyl-lysine binding) and recruiting BRD2 to the rDNA promoter and transcribed regions via association with upstream binding factor (UBF). BRD2 then recruits the MYST-type acetyltransferase KAT7, increasing local histone H4 acetylation. Independently, LYAR also binds a BRD4-KAT7 complex that is recruited to rDNA to promote acetylation of both H3 and H4. LYAR had no effect on rDNA methylation or RNA Pol I subunit binding, indicating selective effect on local chromatin acetylation.","method":"Co-IP, ChIP-seq, siRNA knockdown, ChIP-qPCR, histone modification analysis, rRNA synthesis assay","journal":"Nucleic Acids Research","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (Co-IP, ChIP-seq, functional rRNA assay) in a comprehensive mechanistic study","pmids":["31504794"],"is_preprint":false},{"year":2019,"finding":"LYAR expression is induced by IFN-β during virus infection. LYAR acts as a negative regulator of innate immunity by interacting with phosphorylated IRF3, impeding IRF3's DNA-binding capacity and thereby suppressing IFN-β transcription and downstream ISG expression. LYAR also inhibits NF-κB-mediated proinflammatory cytokine expression.","method":"Co-IP (LYAR–phospho-IRF3 interaction), reporter assays, siRNA knockdown, viral infection assays","journal":"Journal of Virology","confidence":"High","confidence_rationale":"Tier 2 — Co-IP of specific phospho-IRF3 interaction with functional reporter and ISG expression assays","pmids":["31413131"],"is_preprint":false},{"year":2019,"finding":"LYAR binds the 5'-GGTTAT-3' motif within the 5'-UTR of the Aγ-globin gene. The rs368698783 G>A polymorphism within this binding site attenuates LYAR binding efficiency as demonstrated by surface plasmon resonance using crude nuclear extracts, LYAR-enriched lysates, and recombinant LYAR, with findings confirmed by molecular docking.","method":"Surface plasmon resonance (SPR-BIA) with recombinant and endogenous LYAR, molecular docking","journal":"Analytical and Bioanalytical Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — quantitative biophysical binding assay with multiple protein sources, single lab","pmids":["31300855"],"is_preprint":false},{"year":2021,"finding":"LYAR promotes colorectal cancer cell migration and invasion by transcriptionally upregulating FSCN1 (fascin-1). FSCN1 knockdown suppressed subcutaneous tumorigenesis and downregulated FASN and SCD (key fatty acid synthesis enzymes), linking LYAR-FSCN1 axis to fatty acid metabolism.","method":"Microarray analysis, ChIP assay, gene reporter assay, siRNA knockdown, rescue experiments, xenograft assays","journal":"Oxidative Medicine and Cellular Longevity","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and reporter assay with in vivo xenograft validation, single lab","pmids":["35069968"],"is_preprint":false},{"year":2012,"finding":"Lyar gene-trap mutant mouse embryonic fibroblasts showed impaired growth coincident with increased p53 and p21 protein levels, suggesting activation of a p53-mediated stress response upon LYAR loss. Compound Lyar/p53 mutant female mice displayed high rates of neural tube defect (exencephaly), establishing a genetic interaction between Lyar and p53 in neural tube closure.","method":"Gene-trap mutagenesis, MEF growth assays, Western blotting (p53/p21), genetic epistasis in compound mutant mice","journal":"Birth Defects Research Part A","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis in vivo with molecular readouts, single lab","pmids":["22815056"],"is_preprint":false},{"year":2026,"finding":"CRISPR/Cas9 knockout of Lyar in mouse ESCs reduced proliferation, increased apoptosis, and elevated p53 and p21 protein levels, confirming p53-p21 pathway activation upon LYAR loss. Lyar KO also impaired multi-lineage differentiation, with downregulation of mesoderm (Gsc, T), endoderm (Gata4, Sox17), and ectoderm (Pax6) markers in embryoid body formation.","method":"CRISPR/Cas9 knockout, cell cycle analysis, apoptosis assay, Western blotting, embryoid body differentiation assay, qPCR","journal":"Frontiers in Genetics","confidence":"Medium","confidence_rationale":"Tier 2 — clean KO with defined molecular and cellular phenotypes using multiple orthogonal methods","pmids":["41938621"],"is_preprint":false},{"year":2026,"finding":"LYAR is expressed throughout preimplantation development and progressively translocates from cytoplasm/nucleus into the nucleolus as development proceeds. Knockdown of LYAR at the pronuclear stage reduced inner cell mass (ICM) number after first lineage differentiation and decreased newly synthesized rRNA (EU staining). Manipulation in individual blastomeres at the 2-cell stage altered their contribution to the ICM, linking LYAR-dependent rDNA transcription and pre-rRNA processing to ICM specification.","method":"Immunofluorescence, qPCR, siRNA microinjection, EU staining (nascent rRNA), blastomere-specific manipulation","journal":"Anatomia Histologia Embryologia","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization with functional consequence via multiple methods, single lab","pmids":["41404914"],"is_preprint":false}],"current_model":"LYAR is a nucleolar zinc finger protein that promotes cell growth and rRNA synthesis by recruiting BRD2-KAT7 and BRD4-KAT7 complexes to rDNA loci to enhance local histone H3/H4 acetylation; it also acts as a transcription factor binding specific gene promoters (including Aγ-globin, LGALS1, and FSCN1), forms a complex with PRMT5 to suppress oxidative stress genes downstream of N-Myc, interacts with phosphorylated IRF3 to negatively regulate IFN-β innate immune responses, facilitates influenza A vRNP assembly by interacting with viral RNP subunits, and its loss activates p53-p21-mediated growth arrest and impairs embryonic lineage specification."},"narrative":{"teleology":[{"year":1993,"claim":"Identification of LYAR as a nucleolar zinc finger protein whose overexpression drives tumorigenesis established that a previously unknown nucleolar factor could directly promote cell growth.","evidence":"cDNA cloning, immunolocalization to nucleolus, retroviral overexpression with nude mouse tumor assay in fibroblasts","pmids":["8491376"],"confidence":"High","gaps":["DNA-binding target sites were not identified","Mechanism linking nucleolar localization to growth promotion was unknown","Endogenous loss-of-function phenotype not tested"]},{"year":2012,"claim":"Gene-trap mutagenesis revealed that LYAR loss activates p53–p21 growth arrest and genetically interacts with p53 in neural tube closure, providing the first endogenous loss-of-function evidence that LYAR is required for normal growth and development.","evidence":"Gene-trap mutant MEFs with Western blot for p53/p21; compound Lyar/p53 mutant mice exhibiting exencephaly","pmids":["22815056"],"confidence":"Medium","gaps":["Molecular link between LYAR loss and p53 stabilization was not defined","Single lab; independent confirmation in other mouse models not available","Whether nucleolar stress mediates the p53 response was untested"]},{"year":2014,"claim":"Discovery that LYAR associates with 60S ribosomal subunits and stimulates translation in vitro extended its functional repertoire beyond transcription to translational control.","evidence":"Proteomic survey, subcellular fractionation and ultracentrifugation in rodent testis and cancer cells, in vitro translation assay","pmids":["24990247"],"confidence":"Medium","gaps":["No ribosome profiling or in vivo translation data","Specificity of LYAR effect on particular mRNAs not addressed","Single lab finding without independent replication"]},{"year":2015,"claim":"ChIP and reporter assays demonstrated that LYAR functions as a transcription factor at the LGALS1 promoter, establishing its role in transcriptional regulation of migration-related genes in colorectal cancer.","evidence":"ChIP, gene reporter assay, siRNA knockdown with rescue by ectopic galectin-1 in colorectal cancer cells","pmids":["26413750"],"confidence":"Medium","gaps":["Genome-wide binding profile of LYAR was not determined","Whether LYAR activates LGALS1 in non-cancer contexts was unclear","Direct DNA-binding motif specificity not fully defined"]},{"year":2017,"claim":"Placing LYAR downstream of N-Myc and in complex with PRMT5, with epistatic rescue by antioxidant treatment and CHAC1 knockdown, defined a pathway through which LYAR suppresses oxidative stress to maintain neuroblastoma cell viability.","evidence":"N-Myc ChIP on LYAR promoter, LYAR–PRMT5 co-IP, genome-wide expression profiling, NAC and CHAC1 siRNA rescue in neuroblastoma cells","pmids":["28686580"],"confidence":"High","gaps":["Direct LYAR–PRMT5 target genes on chromatin were not mapped","Whether PRMT5 catalytic activity is required for LYAR function was not tested","Relevance outside neuroblastoma not demonstrated"]},{"year":2018,"claim":"Demonstration that LYAR directly recruits BRD2 to the Nanog promoter via a specific interaction domain, and that this is required for proper differentiation kinetics, revealed a chromatin-recruitment mechanism linking LYAR to lineage specification.","evidence":"ChIP, domain deletion mutagenesis of Lyar, BET inhibitor treatment, differentiation assays in ESCs","pmids":["29505757"],"confidence":"High","gaps":["Whether BRD2 recruitment by LYAR extends genome-wide beyond Nanog was unknown","Structural basis of the LYAR–BRD2 interaction was not resolved","Relationship to the rDNA-specific BRD2 recruitment discovered later was not yet connected"]},{"year":2018,"claim":"Identification of LYAR as a host factor that interacts with influenza A vRNP subunits and enhances vRNP assembly revealed an unexpected role for this nucleolar protein in viral RNA replication.","evidence":"AP-MS, co-IP, subcellular fractionation showing LYAR relocalization, viral RNA synthesis assays upon LYAR knockdown","pmids":["30209172"],"confidence":"High","gaps":["Specific vRNP subunit interface with LYAR was not mapped","Whether LYAR supports replication of other RNA viruses was not tested","Mechanism of LYAR nucleolar-to-nucleoplasm translocation upon infection not defined"]},{"year":2019,"claim":"Comprehensive mechanistic dissection showed that LYAR recruits both BRD2–KAT7 and BRD4–KAT7 acetyltransferase complexes to rDNA via UBF, selectively enhancing H3/H4 acetylation and rRNA transcription — resolving how LYAR promotes ribosome biogenesis at the chromatin level.","evidence":"Co-IP, ChIP-seq, ChIP-qPCR, siRNA knockdown, histone modification analysis, rRNA synthesis assay","pmids":["31504794"],"confidence":"High","gaps":["Structural basis of LYAR–UBF and LYAR–BRD4 interactions not resolved","Whether this mechanism operates in all cell types or is context-dependent was not examined","Connection between local histone acetylation changes and RNA Pol I processivity was not directly tested"]},{"year":2019,"claim":"Discovery that LYAR binds phosphorylated IRF3 and suppresses IFN-β transcription and NF-κB signaling defined LYAR as a negative regulator of innate antiviral immunity, extending its function beyond growth and ribosome biogenesis.","evidence":"Co-IP of LYAR with phospho-IRF3, reporter assays, siRNA knockdown, viral infection assays","pmids":["31413131"],"confidence":"High","gaps":["Whether LYAR–IRF3 interaction is direct or bridged was not fully resolved","In vivo immune phenotype of LYAR loss was not tested","Relationship between innate immune suppression and LYAR's nucleolar functions unclear"]},{"year":2019,"claim":"Biophysical characterization of LYAR binding to the 5′-GGTTAT-3′ motif in the Aγ-globin 5′-UTR, disrupted by rs368698783, provided quantitative evidence for sequence-specific DNA recognition by LYAR and its potential relevance to hemoglobin regulation.","evidence":"Surface plasmon resonance with recombinant and endogenous LYAR, molecular docking","pmids":["31300855"],"confidence":"Medium","gaps":["Functional consequence of LYAR binding on Aγ-globin expression was not tested in cells","Clinical significance of rs368698783 was not established","Whether this motif represents a general LYAR recognition sequence genome-wide was not addressed"]},{"year":2021,"claim":"Identification of FSCN1 as a direct LYAR transcriptional target linked LYAR-driven tumor migration to fatty acid metabolism through downstream regulation of FASN and SCD.","evidence":"Microarray, ChIP, reporter assay, siRNA knockdown with rescue, xenograft in colorectal cancer cells","pmids":["35069968"],"confidence":"Medium","gaps":["Whether LYAR directly regulates FASN/SCD or acts solely via FSCN1 was not distinguished","Metabolomic confirmation of fatty acid changes upon LYAR manipulation was not provided","Single lab; independent validation needed"]},{"year":2026,"claim":"CRISPR knockout of Lyar in mouse ESCs confirmed p53–p21 activation and further demonstrated that LYAR is required for multi-lineage (mesoderm, endoderm, ectoderm) differentiation capacity, while preimplantation studies showed LYAR-dependent rRNA synthesis is critical for inner cell mass specification.","evidence":"CRISPR/Cas9 KO in ESCs with cell cycle/apoptosis analysis, embryoid body differentiation, and siRNA microinjection at pronuclear/2-cell stage with EU staining for nascent rRNA","pmids":["41938621","41404914"],"confidence":"Medium","gaps":["Both studies from single labs; independent replication pending","Whether p53 activation upon LYAR loss is a direct nucleolar stress response or indirect was not determined","Transcriptomic or epigenomic changes at rDNA loci in LYAR-null embryos were not profiled"]},{"year":null,"claim":"A structural model of LYAR's zinc finger domain bound to DNA, and a unified understanding of how its nucleolar, transcriptional, and immune-regulatory functions are coordinated across cell types, remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal or cryo-EM structure of LYAR or its complexes is available","Genome-wide LYAR ChIP-seq in multiple cell types has not been reported","Whether the p53 activation upon LYAR loss reflects nucleolar stress signaling has not been formally tested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,9,10]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,4,7,10]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[7]}],"localization":[{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[0,13]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,6,13]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,6]}],"pathway":[{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[5,7]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[5,7]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,4,7,10]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[7,13]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[8]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[5,12,13]}],"complexes":["LYAR–BRD2–KAT7","LYAR–BRD4–KAT7","LYAR–PRMT5"],"partners":["BRD2","BRD4","KAT7","PRMT5","UBF","IRF3","UBTF"],"other_free_text":[]},"mechanistic_narrative":"LYAR is a nucleolar zinc finger protein that couples ribosomal DNA transcription, chromatin remodeling, and transcription factor activity to cell growth and differentiation. It promotes rDNA transcription by recruiting BRD2–KAT7 and BRD4–KAT7 complexes to rDNA loci via association with upstream binding factor (UBF), increasing local histone H3 and H4 acetylation without affecting rDNA methylation or RNA Pol I subunit occupancy [PMID:31504794]. LYAR also functions as a sequence-specific transcription factor at gene promoters (LGALS1, FSCN1, Aγ-globin), forms a complex with PRMT5 to suppress oxidative stress genes downstream of N-Myc [PMID:28686580, PMID:26413750, PMID:35069968], negatively regulates IFN-β innate immune signaling by binding phosphorylated IRF3 and impairing its DNA-binding capacity [PMID:31413131], and its loss activates the p53–p21 growth arrest pathway and impairs multi-lineage embryonic differentiation and preimplantation inner cell mass specification [PMID:22815056, PMID:41938621, PMID:41404914]."},"prefetch_data":{"uniprot":{"accession":"Q9NX58","full_name":"Cell growth-regulating nucleolar protein","aliases":[],"length_aa":379,"mass_kda":43.6,"function":"Plays a role in the maintenance of the appropriate processing of 47S/45S pre-rRNA to 32S/30S pre-rRNAs and their subsequent processing to produce 18S and 28S rRNAs (PubMed:24495227). Also acts at the level of transcription regulation. Along with PRMT5, binds the gamma-globin (HBG1/HBG2) promoter and represses its expression (PubMed:25092918). In neuroblastoma cells, may also repress the expression of oxidative stress genes, including CHAC1, HMOX1, SLC7A11, ULBP1 and SNORD41 that encodes a small nucleolar RNA (PubMed:28686580). Preferentially binds to a DNA motif containing 5'-GGTTAT-3' (PubMed:25092918). Negatively regulates the antiviral innate immune response by targeting IRF3 and impairing its DNA-binding activity (PubMed:31413131). In addition, inhibits NF-kappa-B-mediated expression of pro-inflammatory cytokines (PubMed:31413131). Stimulates phagocytosis of photoreceptor outer segments by retinal pigment epithelial cells (By similarity). Prevents nucleolin/NCL self-cleavage, maintaining a normal steady-state level of NCL protein in undifferentiated embryonic stem cells (ESCs), which in turn is essential for ESC self-renewal (By similarity)","subcellular_location":"Nucleus; Nucleus, nucleolus; Cytoplasm; Cell projection, cilium, photoreceptor outer segment","url":"https://www.uniprot.org/uniprotkb/Q9NX58/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LYAR","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CALM3","stoichiometry":0.2},{"gene":"CAPRIN1","stoichiometry":0.2},{"gene":"CAPZB","stoichiometry":0.2},{"gene":"DRG1","stoichiometry":0.2},{"gene":"G3BP2","stoichiometry":0.2},{"gene":"METAP2","stoichiometry":0.2},{"gene":"NPM1","stoichiometry":0.2},{"gene":"PSPC1","stoichiometry":0.2},{"gene":"RACK1","stoichiometry":0.2},{"gene":"RBM42","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/LYAR","total_profiled":1310},"omim":[{"mim_id":"617684","title":"Ly1 ANTIBODY-REACTIVE PROTEIN; LYAR","url":"https://www.omim.org/entry/617684"},{"mim_id":"142200","title":"HEMOGLOBIN, GAMMA A; HBG1","url":"https://www.omim.org/entry/142200"},{"mim_id":"141749","title":"FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 1; HBFQTL1","url":"https://www.omim.org/entry/141749"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoli rim","reliability":"Enhanced"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Nucleoli","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"testis","ntpm":95.4}],"url":"https://www.proteinatlas.org/search/LYAR"},"hgnc":{"alias_symbol":["ZLYAR"],"prev_symbol":[]},"alphafold":{"accession":"Q9NX58","domains":[{"cath_id":"3.30.1490.490","chopping":"4-59","consensus_level":"high","plddt":89.7395,"start":4,"end":59},{"cath_id":"1.10.10,1.10.238","chopping":"312-378","consensus_level":"high","plddt":91.2737,"start":312,"end":378},{"cath_id":"1.10.150","chopping":"70-143","consensus_level":"high","plddt":83.8072,"start":70,"end":143}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NX58","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NX58-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NX58-F1-predicted_aligned_error_v6.png","plddt_mean":70.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LYAR","jax_strain_url":"https://www.jax.org/strain/search?query=LYAR"},"sequence":{"accession":"Q9NX58","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NX58.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NX58/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NX58"}},"corpus_meta":[{"pmid":"8491376","id":"PMC_8491376","title":"LYAR, a novel nucleolar protein with zinc finger DNA-binding motifs, is involved in cell growth regulation.","date":"1993","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/8491376","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31504794","id":"PMC_31504794","title":"LYAR potentiates rRNA synthesis by recruiting BRD2/4 and the MYST-type acetyltransferase KAT7 to rDNA.","date":"2019","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/31504794","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35069968","id":"PMC_35069968","title":"LYAR Promotes Colorectal Cancer Progression by Upregulating FSCN1 Expression and Fatty Acid Metabolism.","date":"2021","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/35069968","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30209172","id":"PMC_30209172","title":"The Nucleolar Protein LYAR Facilitates Ribonucleoprotein Assembly of Influenza A Virus.","date":"2018","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/30209172","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26413750","id":"PMC_26413750","title":"LYAR promotes colorectal cancer cell mobility by activating galectin-1 expression.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26413750","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31413131","id":"PMC_31413131","title":"LYAR Suppresses Beta Interferon Induction by Targeting Phosphorylated Interferon Regulatory Factor 3.","date":"2019","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/31413131","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28686580","id":"PMC_28686580","title":"Upregulation of LYAR induces neuroblastoma cell proliferation and survival.","date":"2017","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/28686580","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22815056","id":"PMC_22815056","title":"Mutations in Lyar and p53 are synergistically lethal in female mice.","date":"2012","source":"Birth defects research. Part A, Clinical and molecular teratology","url":"https://pubmed.ncbi.nlm.nih.gov/22815056","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24990247","id":"PMC_24990247","title":"Lyar, a cell growth-regulating zinc finger protein, was identified to be associated with cytoplasmic ribosomes in male germ and cancer cells.","date":"2014","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24990247","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29505757","id":"PMC_29505757","title":"Lyar-Mediated Recruitment of Brd2 to the Chromatin Attenuates Nanog Downregulation Following Induction of Differentiation.","date":"2018","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29505757","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33111744","id":"PMC_33111744","title":"LINC00355 promoted the progression of lung squamous cell carcinoma through regulating the miR-466/LYAR axis.","date":"2020","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/33111744","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23212345","id":"PMC_23212345","title":"Expression and function of the testis-predominant protein LYAR in mice.","date":"2012","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/23212345","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15761769","id":"PMC_15761769","title":"Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28).","date":"2005","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15761769","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36614221","id":"PMC_36614221","title":"The rs368698783 (G>A) Polymorphism Affecting LYAR Binding to the Aγ-Globin Gene Is Associated with High Fetal Hemoglobin (HbF) in β-Thalassemia Erythroid Precursor Cells Treated with HbF Inducers.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36614221","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31300855","id":"PMC_31300855","title":"Surface plasmon resonance based analysis of the binding of LYAR protein to the rs368698783 (G>A) polymorphic Aγ-globin gene sequences mutated in β-thalassemia.","date":"2019","source":"Analytical and bioanalytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31300855","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25735755","id":"PMC_25735755","title":"Lyar Is a New Ligand for Retinal Pigment Epithelial Phagocytosis.","date":"2015","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25735755","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41938621","id":"PMC_41938621","title":"Lyar contributes to cell cycle progression and multi-lineage differentiation in mouse embryonic stem cells.","date":"2026","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41938621","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41511857","id":"PMC_41511857","title":"The therapeutic potential of targeting LYAR in gastric cancer.","date":"2026","source":"Future science OA","url":"https://pubmed.ncbi.nlm.nih.gov/41511857","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41404914","id":"PMC_41404914","title":"LYAR Regulates Ribosomal Genes to Impact the First Lineage Differentiation During Mouse Preimplantation Development.","date":"2026","source":"Anatomia, histologia, embryologia","url":"https://pubmed.ncbi.nlm.nih.gov/41404914","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.10.16.682832","title":"Decoding the human PBMC isonome: Isoform-level resolution with single-cell long-read transcriptomics","date":"2025-10-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.16.682832","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"22658674","id":"PMC_22658674","title":"Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22658674","citation_count":1718,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22681889","id":"PMC_22681889","title":"The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts.","date":"2012","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/22681889","citation_count":973,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11076863","id":"PMC_11076863","title":"DNA cloning using in vitro site-specific recombination.","date":"2000","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/11076863","citation_count":815,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11790298","id":"PMC_11790298","title":"Directed proteomic analysis of the human nucleolus.","date":"2002","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/11790298","citation_count":780,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17353931","id":"PMC_17353931","title":"Large-scale mapping of human protein-protein interactions by mass spectrometry.","date":"2007","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/17353931","citation_count":733,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32680882","id":"PMC_32680882","title":"Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32680882","citation_count":653,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12429849","id":"PMC_12429849","title":"Functional proteomic analysis of human nucleolus.","date":"2002","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/12429849","citation_count":391,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21145461","id":"PMC_21145461","title":"Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21145461","citation_count":318,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21903422","id":"PMC_21903422","title":"Mapping a dynamic innate immunity protein interaction network regulating type I interferon production.","date":"2011","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/21903422","citation_count":286,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11256614","id":"PMC_11256614","title":"Systematic subcellular localization of novel proteins identified by large-scale cDNA sequencing.","date":"2000","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/11256614","citation_count":281,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26949251","id":"PMC_26949251","title":"The cell proliferation antigen Ki-67 organises heterochromatin.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/26949251","citation_count":265,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32160526","id":"PMC_32160526","title":"A Genome-wide ER-phagy Screen Highlights Key Roles of Mitochondrial Metabolism and ER-Resident UFMylation.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/32160526","citation_count":253,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21988832","id":"PMC_21988832","title":"Toward an understanding of the protein interaction network of the human liver.","date":"2011","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/21988832","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29568061","id":"PMC_29568061","title":"An AP-MS- and BioID-compatible MAC-tag enables comprehensive mapping of protein interactions and subcellular localizations.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29568061","citation_count":201,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21516116","id":"PMC_21516116","title":"Next-generation sequencing to generate interactome datasets.","date":"2011","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/21516116","citation_count":200,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32203420","id":"PMC_32203420","title":"Systems analysis of RhoGEF and RhoGAP regulatory proteins reveals spatially organized RAC1 signalling from integrin adhesions.","date":"2020","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32203420","citation_count":194,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":11696,"output_tokens":3172,"usd":0.041334},"stage2":{"model":"claude-opus-4-6","input_tokens":6573,"output_tokens":3233,"usd":0.170535},"total_usd":0.463621,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":22609,"output_tokens":4154,"usd":0.065069},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":7186,"output_tokens":3541,"usd":0.186683}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"LYAR is a nucleolar zinc finger protein with three nuclear localization signals that, when overexpressed in fibroblasts via retroviral vector, increased tumor formation in nude mice, indicating a role in cell growth regulation as a nucleolar oncoprotein.\",\n      \"method\": \"Retroviral overexpression in fibroblasts, immunolocalization, immunoprecipitation/Western blot\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct localization and functional overexpression with tumor phenotype, single study\",\n      \"pmids\": [\"8491376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LYAR associates with cytoplasmic ribosomes, specifically with the 60S large subunit but not polysomes, in rodent testis, and promotes in vitro translation, identifying a role in translational control.\",\n      \"method\": \"Subcellular fractionation, ultracentrifugation of ribosomes, in vitro translation assay, proteomics\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — fractionation with functional in vitro translation assay, single lab\",\n      \"pmids\": [\"24990247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LYAR directly binds the LGALS1 (galectin-1) promoter to upregulate galectin-1 expression, thereby promoting migration and invasion of colorectal cancer cells.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, knockdown rescue experiments\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and reporter assay with rescue, single lab\",\n      \"pmids\": [\"26413750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Lyar localizes to photoreceptor outer segments in the retina and, when released from apoptotic cells, selectively binds shed photoreceptor outer segments and apoptotic cells to stimulate RPE phagocytosis; engulfed vesicles via Lyar-dependent pathway colocalize with phagosome marker Rab7.\",\n      \"method\": \"Open reading frame phage display, immunohistochemistry, functional phagocytosis assay, colocalization with Rab7\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional cloning with phagocytosis assay and colocalization, single lab\",\n      \"pmids\": [\"25735755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"LYAR forms a protein complex with PRMT5 and represses expression of oxidative stress genes including CHAC1, thereby suppressing oxidative stress and promoting neuroblastoma cell proliferation and survival; N-Myc upregulates LYAR by binding its gene promoter.\",\n      \"method\": \"Co-immunoprecipitation (LYAR-PRMT5 complex), siRNA knockdown, genome-wide gene expression analysis, N-Myc ChIP at LYAR promoter\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP for complex, ChIP for N-Myc binding, KD with defined phenotype, single lab\",\n      \"pmids\": [\"28686580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LYAR recruits BRD2 to chromatin at pluripotency gene promoters (e.g., Nanog); loss of LYAR causes BRD2 dissociation from these promoters, impairing proper timing of Nanog downregulation during differentiation, while BET protein depletion does not affect LYAR chromatin occupancy.\",\n      \"method\": \"ChIP, co-immunoprecipitation, truncation mutant of Lyar lacking BRD2-interacting domain, siRNA knockdown\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP, Co-IP, and domain-deletion mutant with functional readout, single lab\",\n      \"pmids\": [\"29505757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"During influenza A virus infection, LYAR translocates from the nucleolus to the nucleoplasm and cytoplasm, interacts with viral RNP subunits (PB1, PB2, PA, NP), and enhances viral RNP assembly, thereby facilitating viral RNA synthesis.\",\n      \"method\": \"Affinity purification-mass spectrometry, co-immunoprecipitation, viral RNA synthesis assay, immunofluorescence localization\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — AP-MS identification, reciprocal Co-IP, functional vRNP assembly assay, localization tracking, multiple orthogonal methods\",\n      \"pmids\": [\"30209172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LYAR enhances rDNA transcription by: (1) binding BRD2 (independently of acetyl-lysine-binding bromodomains) and recruiting it along with KAT7 to rDNA promoter and transcribed regions via upstream binding factor, leading to enhanced H4 acetylation; (2) binding a BRD4-KAT7 complex and recruiting it to rDNA independently of BRD2-KAT7, accelerating acetylation of both H3 and H4. LYAR has no effect on rDNA methylation or RNA Pol I subunit binding.\",\n      \"method\": \"ChIP, co-immunoprecipitation, siRNA knockdown, rRNA synthesis measurement\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (ChIP, Co-IP, KD, rRNA synthesis assay), mechanistic dissection of two distinct complexes, single lab but comprehensive\",\n      \"pmids\": [\"31504794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LYAR interacts with phosphorylated IRF3 and impedes its DNA-binding capacity, thereby suppressing IFN-β transcription and downstream ISG expression; LYAR also inhibits NF-κB-mediated proinflammatory cytokine expression.\",\n      \"method\": \"Co-immunoprecipitation with phospho-IRF3, luciferase reporter assay, IFN-β/ISG expression measurement, NF-κB reporter assay\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP with phospho-IRF3 and functional transcription assays, single lab\",\n      \"pmids\": [\"31413131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LYAR protein binds the 5'-GGTTAT-3' sequence within the 5'-UTR of the Aγ-globin gene; the rs368698783 (G>A) polymorphism in this site attenuates LYAR binding efficiency as measured by surface plasmon resonance with recombinant LYAR and LYAR-enriched lysates.\",\n      \"method\": \"Surface plasmon resonance biospecific interaction analysis (SPR-BIA), molecular docking, recombinant protein binding assay\",\n      \"journal\": \"Analytical and bioanalytical chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — quantitative in vitro binding assay with recombinant protein and SPR, single lab\",\n      \"pmids\": [\"31300855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LYAR directly binds the FSCN1 promoter to upregulate fascin-1 expression, which promotes colorectal cancer cell migration and invasion; FSCN1 knockdown also downregulates fatty acid synthesis genes FASN and SCD.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, microarray analysis, siRNA knockdown, rescue experiment, in vivo xenograft\",\n      \"journal\": \"Oxidative medicine and cellular longevity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and reporter assay with rescue and in vivo validation, single lab\",\n      \"pmids\": [\"35069968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Loss of LYAR in mouse embryonic fibroblasts (MEFs) triggers a cellular stress response characterized by increased p53 and p21 protein levels and impaired cell growth; combined loss of LYAR and p53 in female mice causes neural tube defects (exencephaly), placing LYAR in a p53-mediated developmental checkpoint pathway.\",\n      \"method\": \"Gene-trap mouse model, MEF growth assay, Western blot for p53/p21, genetic epistasis (Lyar/p53 double mutant)\",\n      \"journal\": \"Birth defects research. Part A, Clinical and molecular teratology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with defined molecular mechanism (p53-p21 pathway), multiple readouts\",\n      \"pmids\": [\"22815056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"LYAR deficiency in mouse ESCs activates the p53-p21 pathway, reduces proliferation, increases apoptosis, and impairs multi-lineage differentiation marker expression (mesoderm, endoderm, ectoderm markers) in embryoid body formation.\",\n      \"method\": \"CRISPR/Cas9 knockout, flow cytometry, Western blot for p53/p21, embryoid body formation assay, gene expression analysis\",\n      \"journal\": \"Frontiers in genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined molecular pathway and multiple cellular phenotypes, single lab\",\n      \"pmids\": [\"41938621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"LYAR gradually translocates from the cytoplasm/nucleus to the nucleolus during mouse preimplantation development; LYAR knockdown reduces ICM cell number and impairs first lineage differentiation, and manipulation of LYAR in individual blastomeres affects their contribution to the ICM; LYAR regulates rDNA transcription and pre-rRNA processing.\",\n      \"method\": \"Immunofluorescence, siRNA injection into pronuclear-stage embryos, blastomere injection, EU staining for rRNA synthesis, qPCR for rDNA transcription and pre-rRNA processing\",\n      \"journal\": \"Anatomia, histologia, embryologia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional localization and KD with mechanistic readouts in embryos, single lab\",\n      \"pmids\": [\"41404914\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LYAR is a nucleolar zinc finger protein that localizes predominantly to the nucleolus and regulates cell growth through multiple mechanisms: it recruits BRD2-KAT7 and BRD4-KAT7 complexes to rDNA to enhance histone acetylation and rRNA synthesis; acts as a transcription factor binding specific promoter sequences (e.g., LGALS1, FSCN1, Aγ-globin) to regulate target gene expression; forms a complex with PRMT5 to suppress oxidative stress genes; interacts with phosphorylated IRF3 to suppress innate immune (IFN-β) responses; and, during influenza infection, translocates to the nucleoplasm/cytoplasm where it binds viral RNP components to enhance viral RNA synthesis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries from KEEP papers only.\n\n**Classification:**\n\nRETRIEVED PAPERS:\n1. PMID:8491376 — KEEP (foundational LYAR paper)\n2. PMID:31504794 — KEEP (LYAR mechanism)\n3. PMID:35069968 — KEEP (LYAR in CRC)\n4. PMID:30209172 — KEEP (LYAR in influenza)\n5. PMID:26413750 — KEEP (LYAR in CRC)\n6. PMID:31413131 — KEEP (LYAR innate immunity)\n7. PMID:28686580 — KEEP (LYAR in neuroblastoma)\n8. PMID:22815056 — KEEP (Lyar mouse genetics)\n9. PMID:24990247 — KEEP (Lyar and ribosomes)\n10. PMID:29505757 — KEEP (Lyar-Brd2 in ESCs)\n11. PMID:33111744 — KEEP (LYAR as miR-466 target in lung SCC — describes LYAR as target, mechanistic info present)\n12. PMID:23212345 — KEEP (LYAR expression in testis/spermatogenesis)\n13. PMID:15761769 — EXCLUDE (alias collision: \"LY-ar\" and \"LY-as\" are mouse lymphoma cell line names, not LYAR protein)\n14. PMID:36614221 — KEEP (LYAR binding to Aγ-globin)\n15. PMID:31300855 — KEEP (LYAR binding to Aγ-globin, SPR)\n16. PMID:25735755 — KEEP (Lyar as RPE phagocytosis ligand)\n17. PMID:41938621 — KEEP (Lyar KO in ESCs)\n18. PMID:41511857 — EXCLUDE (expression/prognostic only)\n19. PMID:41404914 — KEEP (LYAR in preimplantation development)\n20. bio_10.1101_2025.10.16.682832 — EXCLUDE (novel isoform discovery, no mechanistic LYAR protein finding)\n\nADDITIONAL PAPERS: Mostly large-scale interactome/proteome studies; none specifically describe LYAR mechanisms. EXCLUDE all (they mention LYAR only as a listed protein).\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"LYAR was identified as a novel nucleolar zinc finger protein containing a zinc finger DNA-binding motif and three nuclear localization signals. Immunolocalization showed predominant nucleolar localization. Overexpression of LYAR in fibroblasts increased tumor formation in nude mice, establishing LYAR as a candidate nucleolar oncoprotein involved in cell growth regulation.\",\n      \"method\": \"cDNA cloning, immunolocalization, Western blot, retroviral overexpression with in vivo tumor assay\",\n      \"journal\": \"Genes & Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — foundational paper with multiple orthogonal methods (immunolocalization, immunoprecipitation, functional tumor assay), highly cited\",\n      \"pmids\": [\"8491376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Lyar was found to associate with cytoplasmic ribosomes in rodent testis and cancer cells, specifically with the 60S large ribosomal subunit but not polysomes. Overexpression of Lyar increased translation in vitro, providing the first experimental link between LYAR and translational control.\",\n      \"method\": \"Proteomic survey, subcellular fractionation, ultracentrifugation, in vitro translation assay\",\n      \"journal\": \"Molecular and Cellular Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple biochemical methods in a single study but single lab\",\n      \"pmids\": [\"24990247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LYAR was characterized as a transcription factor that directly binds the LGALS1 (galectin-1) promoter to upregulate galectin-1 expression, thereby promoting migration and invasion of colorectal cancer cells. Ectopic galectin-1 expression partially rescued migration in LYAR knockdown cells.\",\n      \"method\": \"ChIP assay, gene reporter assay, siRNA knockdown, rescue experiment, migration/invasion assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and reporter assay with rescue experiment, single lab\",\n      \"pmids\": [\"26413750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Lyar was identified as a ligand for retinal pigment epithelial (RPE) phagocytosis. Cytoplasmic Lyar released from apoptotic cells selectively bound to shed photoreceptor outer segments (POSs) and apoptotic cells but not healthy cells, and POS vesicles engulfed via the Lyar-dependent pathway were targeted to Rab7-positive phagosomes.\",\n      \"method\": \"Open reading frame phage display, functional cloning, immunohistochemistry, colocalization with phagosome marker Rab7\",\n      \"journal\": \"Journal of Cellular Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — novel ligand identification with functional phagosome colocalization, single lab\",\n      \"pmids\": [\"25735755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"N-Myc was shown to upregulate LYAR gene expression by binding to its promoter. LYAR forms a protein complex with PRMT5. Knockdown of LYAR upregulated oxidative stress genes including CHAC1 (which depletes glutathione), leading to oxidative stress, growth inhibition, and apoptosis in neuroblastoma cells. Co-treatment with N-acetyl-l-cysteine or CHAC1 siRNA rescued LYAR knockdown phenotypes, placing LYAR in a pathway that suppresses oxidative stress downstream of N-Myc.\",\n      \"method\": \"Promoter ChIP, siRNA knockdown, genome-wide gene expression, co-IP (LYAR-PRMT5 complex), rescue experiments with NAC and CHAC1 siRNA\",\n      \"journal\": \"Cell Death and Differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including promoter binding, complex identification, epistasis rescue, single lab but comprehensive\",\n      \"pmids\": [\"28686580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LYAR selectively recruits BRD2 to chromatin at specific promoters including Nanog. Under differentiation conditions, Lyar-mediated recruitment of Brd2 moderates Nanog downregulation; loss of Lyar leads to impaired Nanog downregulation and defective differentiation. A truncated Lyar lacking the Brd2-interacting domain phenocopied Brd2 depletion, confirming that direct LYAR-BRD2 interaction is required for chromatin recruitment.\",\n      \"method\": \"ChIP, siRNA knockdown, domain deletion mutagenesis (truncated Lyar), BET inhibitor treatment, differentiation assays\",\n      \"journal\": \"Journal of Molecular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP with domain mutagenesis and functional differentiation readout, multiple orthogonal approaches\",\n      \"pmids\": [\"29505757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"During influenza A virus infection, LYAR expression is increased and LYAR translocates from the nucleolus to the nucleoplasm and cytoplasm. LYAR interacts with viral RNP (vRNP) subunits, enhancing vRNP assembly and thereby facilitating viral RNA synthesis and influenza A virus replication.\",\n      \"method\": \"Affinity purification–mass spectrometry (AP-MS), co-IP, subcellular fractionation, viral RNA synthesis assays, knockdown\",\n      \"journal\": \"Journal of Virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — AP-MS identification followed by co-IP validation and functional RNA synthesis assay, mechanistically coherent\",\n      \"pmids\": [\"30209172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LYAR enhances rDNA transcription by binding BRD2 (independent of bromodomain acetyl-lysine binding) and recruiting BRD2 to the rDNA promoter and transcribed regions via association with upstream binding factor (UBF). BRD2 then recruits the MYST-type acetyltransferase KAT7, increasing local histone H4 acetylation. Independently, LYAR also binds a BRD4-KAT7 complex that is recruited to rDNA to promote acetylation of both H3 and H4. LYAR had no effect on rDNA methylation or RNA Pol I subunit binding, indicating selective effect on local chromatin acetylation.\",\n      \"method\": \"Co-IP, ChIP-seq, siRNA knockdown, ChIP-qPCR, histone modification analysis, rRNA synthesis assay\",\n      \"journal\": \"Nucleic Acids Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (Co-IP, ChIP-seq, functional rRNA assay) in a comprehensive mechanistic study\",\n      \"pmids\": [\"31504794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LYAR expression is induced by IFN-β during virus infection. LYAR acts as a negative regulator of innate immunity by interacting with phosphorylated IRF3, impeding IRF3's DNA-binding capacity and thereby suppressing IFN-β transcription and downstream ISG expression. LYAR also inhibits NF-κB-mediated proinflammatory cytokine expression.\",\n      \"method\": \"Co-IP (LYAR–phospho-IRF3 interaction), reporter assays, siRNA knockdown, viral infection assays\",\n      \"journal\": \"Journal of Virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP of specific phospho-IRF3 interaction with functional reporter and ISG expression assays\",\n      \"pmids\": [\"31413131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LYAR binds the 5'-GGTTAT-3' motif within the 5'-UTR of the Aγ-globin gene. The rs368698783 G>A polymorphism within this binding site attenuates LYAR binding efficiency as demonstrated by surface plasmon resonance using crude nuclear extracts, LYAR-enriched lysates, and recombinant LYAR, with findings confirmed by molecular docking.\",\n      \"method\": \"Surface plasmon resonance (SPR-BIA) with recombinant and endogenous LYAR, molecular docking\",\n      \"journal\": \"Analytical and Bioanalytical Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — quantitative biophysical binding assay with multiple protein sources, single lab\",\n      \"pmids\": [\"31300855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LYAR promotes colorectal cancer cell migration and invasion by transcriptionally upregulating FSCN1 (fascin-1). FSCN1 knockdown suppressed subcutaneous tumorigenesis and downregulated FASN and SCD (key fatty acid synthesis enzymes), linking LYAR-FSCN1 axis to fatty acid metabolism.\",\n      \"method\": \"Microarray analysis, ChIP assay, gene reporter assay, siRNA knockdown, rescue experiments, xenograft assays\",\n      \"journal\": \"Oxidative Medicine and Cellular Longevity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and reporter assay with in vivo xenograft validation, single lab\",\n      \"pmids\": [\"35069968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Lyar gene-trap mutant mouse embryonic fibroblasts showed impaired growth coincident with increased p53 and p21 protein levels, suggesting activation of a p53-mediated stress response upon LYAR loss. Compound Lyar/p53 mutant female mice displayed high rates of neural tube defect (exencephaly), establishing a genetic interaction between Lyar and p53 in neural tube closure.\",\n      \"method\": \"Gene-trap mutagenesis, MEF growth assays, Western blotting (p53/p21), genetic epistasis in compound mutant mice\",\n      \"journal\": \"Birth Defects Research Part A\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with molecular readouts, single lab\",\n      \"pmids\": [\"22815056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"CRISPR/Cas9 knockout of Lyar in mouse ESCs reduced proliferation, increased apoptosis, and elevated p53 and p21 protein levels, confirming p53-p21 pathway activation upon LYAR loss. Lyar KO also impaired multi-lineage differentiation, with downregulation of mesoderm (Gsc, T), endoderm (Gata4, Sox17), and ectoderm (Pax6) markers in embryoid body formation.\",\n      \"method\": \"CRISPR/Cas9 knockout, cell cycle analysis, apoptosis assay, Western blotting, embryoid body differentiation assay, qPCR\",\n      \"journal\": \"Frontiers in Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined molecular and cellular phenotypes using multiple orthogonal methods\",\n      \"pmids\": [\"41938621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"LYAR is expressed throughout preimplantation development and progressively translocates from cytoplasm/nucleus into the nucleolus as development proceeds. Knockdown of LYAR at the pronuclear stage reduced inner cell mass (ICM) number after first lineage differentiation and decreased newly synthesized rRNA (EU staining). Manipulation in individual blastomeres at the 2-cell stage altered their contribution to the ICM, linking LYAR-dependent rDNA transcription and pre-rRNA processing to ICM specification.\",\n      \"method\": \"Immunofluorescence, qPCR, siRNA microinjection, EU staining (nascent rRNA), blastomere-specific manipulation\",\n      \"journal\": \"Anatomia Histologia Embryologia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization with functional consequence via multiple methods, single lab\",\n      \"pmids\": [\"41404914\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LYAR is a nucleolar zinc finger protein that promotes cell growth and rRNA synthesis by recruiting BRD2-KAT7 and BRD4-KAT7 complexes to rDNA loci to enhance local histone H3/H4 acetylation; it also acts as a transcription factor binding specific gene promoters (including Aγ-globin, LGALS1, and FSCN1), forms a complex with PRMT5 to suppress oxidative stress genes downstream of N-Myc, interacts with phosphorylated IRF3 to negatively regulate IFN-β innate immune responses, facilitates influenza A vRNP assembly by interacting with viral RNP subunits, and its loss activates p53-p21-mediated growth arrest and impairs embryonic lineage specification.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"LYAR is a nucleolar zinc finger protein that functions as a transcriptional regulator of ribosomal DNA and protein-coding gene promoters, coupling ribosome biogenesis to cell growth, pluripotency, and differentiation. LYAR recruits BRD2-KAT7 and BRD4-KAT7 histone acetyltransferase complexes to rDNA to enhance histone H3/H4 acetylation and rRNA synthesis, and it directly binds promoters of target genes including LGALS1 and FSCN1 to drive their transcription in colorectal cancer cells [PMID:31504794, PMID:26413750, PMID:35069968]. Loss of LYAR activates the p53-p21 stress checkpoint, impairing cell proliferation and multi-lineage differentiation; combined Lyar/p53 loss in mice causes neural tube defects, establishing LYAR as a component of a p53-dependent developmental checkpoint [PMID:22815056, PMID:41938621]. LYAR also suppresses innate immune signaling by binding phosphorylated IRF3 to block IFN-β transcription, and during influenza A infection it translocates from the nucleolus to interact with viral RNP subunits and enhance viral RNA synthesis [PMID:31413131, PMID:30209172].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Establishing LYAR as a nucleolar zinc finger protein linked to cell growth: the first cloning of LYAR revealed its nucleolar localization and showed that overexpression promoted tumorigenesis, raising the question of what molecular function it performs in the nucleolus.\",\n      \"evidence\": \"Retroviral overexpression in fibroblasts with immunolocalization and nude mouse tumorigenesis\",\n      \"pmids\": [\"8491376\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No target genes or molecular mechanism identified\",\n        \"Tumorigenesis shown only by overexpression in one cell type\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrating LYAR's role in a p53-dependent growth checkpoint: loss-of-function analysis showed LYAR deficiency triggers p53-p21 activation and impaired growth, and Lyar/p53 double-mutant mice develop neural tube defects, establishing LYAR as a regulator of a developmental stress response.\",\n      \"evidence\": \"Gene-trap mouse model, MEF growth assay, Western blot for p53/p21, genetic epistasis in Lyar/p53 double mutants\",\n      \"pmids\": [\"22815056\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether LYAR directly represses p53 or acts indirectly through nucleolar stress remains unresolved\",\n        \"Neural tube defect mechanism not dissected at the molecular level\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identifying LYAR as a sequence-specific transcription factor at protein-coding gene promoters: ChIP and reporter assays showed LYAR directly binds the LGALS1 promoter to drive galectin-1 expression and promote cancer cell migration, expanding its role beyond nucleolar function.\",\n      \"evidence\": \"ChIP assay, luciferase reporter, knockdown rescue in colorectal cancer cells\",\n      \"pmids\": [\"26413750\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Genome-wide binding profile not established\",\n        \"DNA recognition motif for protein-coding gene promoters not defined\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealing a LYAR-PRMT5 axis that represses oxidative stress genes: co-immunoprecipitation identified a LYAR-PRMT5 complex that suppresses CHAC1 and other oxidative stress genes, linking LYAR to epigenetic repression and neuroblastoma cell survival downstream of N-Myc.\",\n      \"evidence\": \"Co-IP for LYAR-PRMT5 complex, siRNA knockdown, genome-wide expression profiling, N-Myc ChIP at LYAR promoter\",\n      \"pmids\": [\"28686580\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether LYAR recruits PRMT5 to specific chromatin targets not shown by ChIP\",\n        \"Functional significance of N-Myc-LYAR axis in primary tumors not tested\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Elucidating LYAR's chromatin-recruitment function for BRD2 at pluripotency genes: LYAR recruits BRD2 to Nanog and other pluripotency promoters, and its loss disrupts BRD2 occupancy and the timing of differentiation, establishing LYAR as upstream of BET protein chromatin binding.\",\n      \"evidence\": \"ChIP, co-IP, domain-deletion mutant of LYAR, siRNA knockdown in ESCs\",\n      \"pmids\": [\"29505757\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether LYAR-BRD2 interaction is direct or bridged by additional factors not fully resolved\",\n        \"Whether this mechanism generalizes beyond Nanog unknown\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Discovering LYAR's pro-viral role in influenza infection: upon infection LYAR translocates from the nucleolus to the nucleoplasm/cytoplasm and interacts with all four viral RNP subunits to enhance vRNP assembly, revealing a pathogen-exploitation mechanism.\",\n      \"evidence\": \"AP-MS, reciprocal co-IP, viral RNA synthesis assay, immunofluorescence tracking\",\n      \"pmids\": [\"30209172\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis for LYAR-RNP interaction not determined\",\n        \"Whether this role extends to other RNA viruses untested\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Dissecting the dual BRD2-KAT7 and BRD4-KAT7 recruitment mechanism at rDNA: LYAR independently recruits two histone acetyltransferase complexes to rDNA, enhancing H3 and H4 acetylation and rRNA transcription, providing a mechanistic basis for LYAR's role in ribosome biogenesis.\",\n      \"evidence\": \"ChIP, co-IP, siRNA knockdown, rRNA synthesis measurement\",\n      \"pmids\": [\"31504794\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How LYAR distinguishes rDNA from non-rDNA targets for KAT7 complex recruitment unclear\",\n        \"No structural data on LYAR-BRD2 or LYAR-BRD4 interfaces\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Establishing LYAR as a suppressor of innate immune signaling: LYAR binds phosphorylated IRF3 and blocks its DNA-binding capacity, suppressing IFN-β and ISG expression, connecting LYAR to immune evasion and explaining its pro-viral phenotype.\",\n      \"evidence\": \"Co-IP with phospho-IRF3, luciferase reporter assay, IFN-β/ISG expression measurement\",\n      \"pmids\": [\"31413131\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether LYAR-IRF3 interaction is direct or involves other intermediaries not fully resolved\",\n        \"Physiological relevance of immune suppression in non-viral contexts unknown\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extending LYAR's transcription factor activity to FSCN1: LYAR directly activates the FSCN1 promoter to drive fascin-1 expression, promoting colorectal cancer migration and invasion and linking to downstream fatty acid metabolism, confirming a recurring role as a direct transcriptional activator of invasion-related genes.\",\n      \"evidence\": \"ChIP, luciferase reporter, siRNA knockdown, rescue experiment, xenograft\",\n      \"pmids\": [\"35069968\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No consensus DNA motif defined for LYAR binding at protein-coding promoters\",\n        \"Whether LYAR-driven FSCN1 expression is relevant in non-CRC contexts untested\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Confirming LYAR's requirement for pluripotent stem cell fitness and differentiation: LYAR knockout in mouse ESCs activates the p53-p21 pathway, increases apoptosis, and impairs embryoid body differentiation across all three germ layers, generalizing the p53-dependent checkpoint from MEFs to pluripotent cells.\",\n      \"evidence\": \"CRISPR/Cas9 knockout, flow cytometry, Western blot, embryoid body formation assay\",\n      \"pmids\": [\"41938621\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether differentiation defect is secondary to proliferation/apoptosis defect or reflects a direct role in lineage commitment not distinguished\",\n        \"Single lab study\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Defining LYAR's dynamic nucleolar translocation and function in preimplantation embryos: LYAR moves from cytoplasm/nucleus to the nucleolus during early development, and its knockdown reduces ICM cell number and impairs rDNA transcription and pre-rRNA processing, establishing an in vivo role in ribosome biogenesis during earliest cell fate decisions.\",\n      \"evidence\": \"Immunofluorescence, siRNA injection in pronuclear embryos, blastomere injection, EU incorporation for rRNA synthesis\",\n      \"pmids\": [\"41404914\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism by which LYAR relocalization is regulated during development unknown\",\n        \"Relationship between rRNA processing defect and ICM specification not causally dissected\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the genome-wide DNA-binding specificity of LYAR, whether its p53-checkpoint role is a direct consequence of impaired ribosome biogenesis (nucleolar stress), and the structural basis for its interactions with BRD2, BRD4, PRMT5, and IRF3.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No genome-wide ChIP-seq defining LYAR's complete cistrome\",\n        \"No structural data (crystal/cryo-EM) for LYAR or its complexes\",\n        \"Causal relationship between rDNA/ribosome biogenesis defect and p53 activation not formally tested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [2, 7, 9, 10]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 7, 10]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [0, 7, 13]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 6, 13]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 7, 10]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [5, 7]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [6, 8]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [11, 12]}\n    ],\n    \"complexes\": [\n      \"BRD2-KAT7 complex\",\n      \"BRD4-KAT7 complex\",\n      \"LYAR-PRMT5 complex\"\n    ],\n    \"partners\": [\n      \"BRD2\",\n      \"BRD4\",\n      \"KAT7\",\n      \"PRMT5\",\n      \"IRF3\",\n      \"PB1\",\n      \"PB2\",\n      \"NP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"LYAR is a nucleolar zinc finger protein that couples ribosomal DNA transcription, chromatin remodeling, and transcription factor activity to cell growth and differentiation. It promotes rDNA transcription by recruiting BRD2–KAT7 and BRD4–KAT7 complexes to rDNA loci via association with upstream binding factor (UBF), increasing local histone H3 and H4 acetylation without affecting rDNA methylation or RNA Pol I subunit occupancy [PMID:31504794]. LYAR also functions as a sequence-specific transcription factor at gene promoters (LGALS1, FSCN1, Aγ-globin), forms a complex with PRMT5 to suppress oxidative stress genes downstream of N-Myc [PMID:28686580, PMID:26413750, PMID:35069968], negatively regulates IFN-β innate immune signaling by binding phosphorylated IRF3 and impairing its DNA-binding capacity [PMID:31413131], and its loss activates the p53–p21 growth arrest pathway and impairs multi-lineage embryonic differentiation and preimplantation inner cell mass specification [PMID:22815056, PMID:41938621, PMID:41404914].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Identification of LYAR as a nucleolar zinc finger protein whose overexpression drives tumorigenesis established that a previously unknown nucleolar factor could directly promote cell growth.\",\n      \"evidence\": \"cDNA cloning, immunolocalization to nucleolus, retroviral overexpression with nude mouse tumor assay in fibroblasts\",\n      \"pmids\": [\"8491376\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"DNA-binding target sites were not identified\",\n        \"Mechanism linking nucleolar localization to growth promotion was unknown\",\n        \"Endogenous loss-of-function phenotype not tested\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Gene-trap mutagenesis revealed that LYAR loss activates p53–p21 growth arrest and genetically interacts with p53 in neural tube closure, providing the first endogenous loss-of-function evidence that LYAR is required for normal growth and development.\",\n      \"evidence\": \"Gene-trap mutant MEFs with Western blot for p53/p21; compound Lyar/p53 mutant mice exhibiting exencephaly\",\n      \"pmids\": [\"22815056\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Molecular link between LYAR loss and p53 stabilization was not defined\",\n        \"Single lab; independent confirmation in other mouse models not available\",\n        \"Whether nucleolar stress mediates the p53 response was untested\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that LYAR associates with 60S ribosomal subunits and stimulates translation in vitro extended its functional repertoire beyond transcription to translational control.\",\n      \"evidence\": \"Proteomic survey, subcellular fractionation and ultracentrifugation in rodent testis and cancer cells, in vitro translation assay\",\n      \"pmids\": [\"24990247\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No ribosome profiling or in vivo translation data\",\n        \"Specificity of LYAR effect on particular mRNAs not addressed\",\n        \"Single lab finding without independent replication\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"ChIP and reporter assays demonstrated that LYAR functions as a transcription factor at the LGALS1 promoter, establishing its role in transcriptional regulation of migration-related genes in colorectal cancer.\",\n      \"evidence\": \"ChIP, gene reporter assay, siRNA knockdown with rescue by ectopic galectin-1 in colorectal cancer cells\",\n      \"pmids\": [\"26413750\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Genome-wide binding profile of LYAR was not determined\",\n        \"Whether LYAR activates LGALS1 in non-cancer contexts was unclear\",\n        \"Direct DNA-binding motif specificity not fully defined\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Placing LYAR downstream of N-Myc and in complex with PRMT5, with epistatic rescue by antioxidant treatment and CHAC1 knockdown, defined a pathway through which LYAR suppresses oxidative stress to maintain neuroblastoma cell viability.\",\n      \"evidence\": \"N-Myc ChIP on LYAR promoter, LYAR–PRMT5 co-IP, genome-wide expression profiling, NAC and CHAC1 siRNA rescue in neuroblastoma cells\",\n      \"pmids\": [\"28686580\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct LYAR–PRMT5 target genes on chromatin were not mapped\",\n        \"Whether PRMT5 catalytic activity is required for LYAR function was not tested\",\n        \"Relevance outside neuroblastoma not demonstrated\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstration that LYAR directly recruits BRD2 to the Nanog promoter via a specific interaction domain, and that this is required for proper differentiation kinetics, revealed a chromatin-recruitment mechanism linking LYAR to lineage specification.\",\n      \"evidence\": \"ChIP, domain deletion mutagenesis of Lyar, BET inhibitor treatment, differentiation assays in ESCs\",\n      \"pmids\": [\"29505757\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether BRD2 recruitment by LYAR extends genome-wide beyond Nanog was unknown\",\n        \"Structural basis of the LYAR–BRD2 interaction was not resolved\",\n        \"Relationship to the rDNA-specific BRD2 recruitment discovered later was not yet connected\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identification of LYAR as a host factor that interacts with influenza A vRNP subunits and enhances vRNP assembly revealed an unexpected role for this nucleolar protein in viral RNA replication.\",\n      \"evidence\": \"AP-MS, co-IP, subcellular fractionation showing LYAR relocalization, viral RNA synthesis assays upon LYAR knockdown\",\n      \"pmids\": [\"30209172\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Specific vRNP subunit interface with LYAR was not mapped\",\n        \"Whether LYAR supports replication of other RNA viruses was not tested\",\n        \"Mechanism of LYAR nucleolar-to-nucleoplasm translocation upon infection not defined\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Comprehensive mechanistic dissection showed that LYAR recruits both BRD2–KAT7 and BRD4–KAT7 acetyltransferase complexes to rDNA via UBF, selectively enhancing H3/H4 acetylation and rRNA transcription — resolving how LYAR promotes ribosome biogenesis at the chromatin level.\",\n      \"evidence\": \"Co-IP, ChIP-seq, ChIP-qPCR, siRNA knockdown, histone modification analysis, rRNA synthesis assay\",\n      \"pmids\": [\"31504794\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of LYAR–UBF and LYAR–BRD4 interactions not resolved\",\n        \"Whether this mechanism operates in all cell types or is context-dependent was not examined\",\n        \"Connection between local histone acetylation changes and RNA Pol I processivity was not directly tested\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Discovery that LYAR binds phosphorylated IRF3 and suppresses IFN-β transcription and NF-κB signaling defined LYAR as a negative regulator of innate antiviral immunity, extending its function beyond growth and ribosome biogenesis.\",\n      \"evidence\": \"Co-IP of LYAR with phospho-IRF3, reporter assays, siRNA knockdown, viral infection assays\",\n      \"pmids\": [\"31413131\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether LYAR–IRF3 interaction is direct or bridged was not fully resolved\",\n        \"In vivo immune phenotype of LYAR loss was not tested\",\n        \"Relationship between innate immune suppression and LYAR's nucleolar functions unclear\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Biophysical characterization of LYAR binding to the 5′-GGTTAT-3′ motif in the Aγ-globin 5′-UTR, disrupted by rs368698783, provided quantitative evidence for sequence-specific DNA recognition by LYAR and its potential relevance to hemoglobin regulation.\",\n      \"evidence\": \"Surface plasmon resonance with recombinant and endogenous LYAR, molecular docking\",\n      \"pmids\": [\"31300855\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Functional consequence of LYAR binding on Aγ-globin expression was not tested in cells\",\n        \"Clinical significance of rs368698783 was not established\",\n        \"Whether this motif represents a general LYAR recognition sequence genome-wide was not addressed\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of FSCN1 as a direct LYAR transcriptional target linked LYAR-driven tumor migration to fatty acid metabolism through downstream regulation of FASN and SCD.\",\n      \"evidence\": \"Microarray, ChIP, reporter assay, siRNA knockdown with rescue, xenograft in colorectal cancer cells\",\n      \"pmids\": [\"35069968\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether LYAR directly regulates FASN/SCD or acts solely via FSCN1 was not distinguished\",\n        \"Metabolomic confirmation of fatty acid changes upon LYAR manipulation was not provided\",\n        \"Single lab; independent validation needed\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"CRISPR knockout of Lyar in mouse ESCs confirmed p53–p21 activation and further demonstrated that LYAR is required for multi-lineage (mesoderm, endoderm, ectoderm) differentiation capacity, while preimplantation studies showed LYAR-dependent rRNA synthesis is critical for inner cell mass specification.\",\n      \"evidence\": \"CRISPR/Cas9 KO in ESCs with cell cycle/apoptosis analysis, embryoid body differentiation, and siRNA microinjection at pronuclear/2-cell stage with EU staining for nascent rRNA\",\n      \"pmids\": [\"41938621\", \"41404914\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Both studies from single labs; independent replication pending\",\n        \"Whether p53 activation upon LYAR loss is a direct nucleolar stress response or indirect was not determined\",\n        \"Transcriptomic or epigenomic changes at rDNA loci in LYAR-null embryos were not profiled\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A structural model of LYAR's zinc finger domain bound to DNA, and a unified understanding of how its nucleolar, transcriptional, and immune-regulatory functions are coordinated across cell types, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No crystal or cryo-EM structure of LYAR or its complexes is available\",\n        \"Genome-wide LYAR ChIP-seq in multiple cell types has not been reported\",\n        \"Whether the p53 activation upon LYAR loss reflects nucleolar stress signaling has not been formally tested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 9, 10]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 4, 7, 10]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [0, 13]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 6, 13]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [5, 7]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [5, 7]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 4, 7, 10]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [7, 13]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [5, 12, 13]}\n    ],\n    \"complexes\": [\n      \"LYAR–BRD2–KAT7\",\n      \"LYAR–BRD4–KAT7\",\n      \"LYAR–PRMT5\"\n    ],\n    \"partners\": [\n      \"BRD2\",\n      \"BRD4\",\n      \"KAT7\",\n      \"PRMT5\",\n      \"UBF\",\n      \"IRF3\",\n      \"UBTF\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}